Welcome to our dedicated page for Tg Therapeutics news (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on Tg Therapeutics stock.
TG Therapeutics develops and commercializes therapies for B-cell diseases, with news centered on BRIUMVI (ublituximab-xiiy), its anti-CD20 monoclonal antibody for adult patients with relapsing forms of multiple sclerosis. Company updates commonly cover U.S. net product revenue, global revenue targets, commercial demand, and international commercialization economics tied to BRIUMVI.
Recurring developments also include clinical and real-world data for BRIUMVI in relapsing multiple sclerosis, presentations and publications from multiple sclerosis studies, and development work on a subcutaneous formulation. Corporate news includes financing arrangements, share repurchase authorization updates, operating-expense guidance, and business outlook commentary alongside quarterly and annual results.
TG Therapeutics (NASDAQ:TGTX) reported positive topline Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis (MG) and started a potentially registration-directed randomized Phase 2 trial.
In Phase 1 (n=11), 82% achieved MG-ADL MCID with a mean 4.6-point improvement; BRIUMVI was generally well tolerated.
TG Therapeutics (NASDAQ:TGTX) reported positive Phase 1 results for a high‑concentration subcutaneous formulation of BRIUMVI (ublituximab-xiiy) for multiple sclerosis.
PK/PD data and modeling suggest quarterly and every‑other‑month subcutaneous dosing can achieve non‑inferior 24‑week drug exposure versus IV BRIUMVI, with mean bioavailability >60% and no new safety signals.
More than 100 patients received treatment, with >225 subcutaneous injections. Subcutaneous dosing showed B‑cell depletion consistent with IV BRIUMVI and was generally well tolerated, supporting the 400 mg/2 mL quarterly regimen now under evaluation in a fully enrolled Phase 3 trial, with top‑line data expected around late 2026 to early 2027.
TG Therapeutics (NASDAQ:TGTX) announced that Chairman and CEO Michael S. Weiss will participate in the Goldman Sachs 47th Annual Healthcare Conference at the Loews Miami Beach Hotel in Florida from June 8-10, 2026.
A fireside chat is scheduled for Tuesday, June 9, 2026, at 2:00 PM ET, with a live webcast available on the Events page in the Investors & Media section of the company website.
TG Therapeutics (NASDAQ:TGTX) reported post-hoc pooled data from Phase 3 ULTIMATE I & II trials of BRIUMVI (ublituximab) in treatment-naive adults with relapsing multiple sclerosis over 96 weeks.
Ublituximab cut annualized relapse rate by 56.7% vs teriflunomide, sharply reduced MRI lesions, and achieved NEDA-3 in 82.7% of patients vs 23.1% on teriflunomide, with greater confirmed disability improvement, including in those treated within three years of symptom onset.
TG Therapeutics (NASDAQ:TGTX) announced that Chairman and CEO Michael S. Weiss will participate in the Jefferies Global Healthcare Conference at the Marriott Marquis in New York City, June 2-4, 2026.
A fireside chat is scheduled for Wednesday, June 3, 2026, at 11:40 AM ET, with a live webcast available on the company’s investor website Events page.
TG Therapeutics (NASDAQ:TGTX) reported positive topline results from the Phase 3b ENHANCE trial of BRIUMVI in relapsing multiple sclerosis.
The study met its primary endpoint, showing bioequivalent exposure between the approved Day 1/Day 15 initiation regimen and a new single 600 mg Day 1 infusion, with comparable safety and fewer infusion reactions in the single-infusion arm. A supplemental BLA filing is targeted for 2H-2026.
TG Therapeutics (NASDAQ:TGTX) outlined four data presentations on BRIUMVI (ublituximab-xiiy) in adults with relapsing multiple sclerosis at the 2026 CMSC meeting in Charlotte, May 27-29, 2026.
Presentations feature Phase 4 ENABLE patient‑reported outcomes, real‑world transition data, infusion tolerability, and the PROVIDE breast milk study.
TG Therapeutics (NASDAQ: TGTX) reported Q1 2026 total global revenue of ~$205 million, including BRIUMVI U.S. net product revenue of $194.8 million. The company raised full-year 2026 revenue guidance to ~$925 million and increased BRIUMVI U.S. guidance to $885–900 million. TG secured $500 million of non-dilutive capital, expanded its buyback program to $300 million, and repurchased $200 million of shares to date. Cash, cash equivalents and investments were $572.8 million as of March 31, 2026. Key near-term milestones include ENHANCE topline data mid-2026 and subcutaneous BRIUMVI topline by year-end 2026/early 2027.
Precision BioSciences (NASDAQ: DTIL) reported Q1 2026 results and operational progress, highlighting $125.8 million in cash on March 31, 2026 and advancement of two wholly owned in vivo programs: PBGENE-HBV (ongoing ELIMINATE-B trial; late-breaking EASL poster) and PBGENE-DMD (FDA IND cleared, Fast Track, first site activated).
Q1 revenue was $10.8 million; net loss was $18.4 million, or $(0.75) per share. Company expects cash runway to support key data milestones through 2028.
TG Therapeutics (NASDAQ: TGTX) will hold a conference call on Wednesday, May 6, 2026 at 8:30 AM ET to discuss first quarter 2026 financial results and provide a business outlook for the rest of 2026.
Michael S. Weiss, Chairman and CEO, will host. A live webcast and a 30-day audio replay will be available on the company's Investors & Media Events page. Financial results will be released in a press release prior to the call.